Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.

This research forms part of a continuous quality improvement initiative. It aims to assess patient compliance of oral therapies by artificial intelligence. It could overcome the limitations of current practices and enhance the responsiveness and accuracy of clinical interventions.

Participants needed: 210
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Grand Hôpital de CharleroiUpdated: Apr 22, 2026Locations: 1
Eligibility criteria

All patients aged 18 and over who are treated in the Haematology Department at t... [+2]

All other patients who did not meet the eligibility criteria

Status: Recruiting

Assessing the Japet.W+ Lumbar Traction Device in Rehabilitation for Patients With Non-specific Mechanical Low Back Pain

The study will include patients suffering from nonspecific mechanical low back pain for more than 6 weeks. Two groups will be compared. A Control group and an Experimental group with the exoskeleton JAPET.W

Participants needed: 60
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Grand Hôpital de CharleroiUpdated: Apr 17, 2026Locations: 1
Eligibility criteria

Nonspecific mechanical low back pain for more than 6 weeks, [+3]

Specific low back pain (infectious, inflammatory, tumorous, or traumatic origin)... [+11]

Status: Recruiting

Evolution of the Patient's Perception of the Use of the Upper Limb After a Stroke During Intensive Rehabilitation

This study is being carried out in the context of rehabilitation after stroke, where persistent upper limb weakness is a major challenge. It aims to explore the relationship between observed function and patients' perceived participation in use.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Grand Hôpital de CharleroiUpdated: Apr 13, 2026Locations: 2
Eligibility criteria

First stroke as defined by the World Health Organization. [+1]

Life expectancy <12 months [+4]

Status: Recruiting

Prospective Observational Study of Diffuse Large-cell B Lymphoma

Diffuse large B-cell lymphoma (DLBCL) represents the most common type of non-Hodgkin lymphoma and is currently a curable malignant disease for many patients with immuno-chemotherapy frontline treatment. However, around 30-40 % of patients, are unresponsive or will experience early relapse. The prognosis of primary refractory patient is poor and the management and treatment are a significant challenge due to the disease heterogeneity and the complex genetic framework. The reasons for refractoriness are various and include genetic abnormalities, alterations in tumor and tumor microenvironment. Patient related factors such as comorbidities can also influence treatment outcome. Recently the progress in Machine learning (ML) showed its usefulness in the procedures used to analyze large and complex datasets. In medicine, machine learning is used to create some predictive tools based on data-driven analytic approach and integration of various risk factors and parameters. Machine learning, as a subdomain of artificial intelligence (AI), has the capability to autonomously uncover patterns within datasets. It offers algorithms that can learn from examples to perform a task automatically.The investigators tested in a previous study five machine learning algorithms to establish a model for predicting the risk of primary refractory DLBCL using parameters obtained from a monocentric dataset. The investigators observed that NB Categorical classifier was the best alternative for building a model in order to predict primary refractory disease in DLBCL patients and the second was XGBoost.The investigators plan to extend this previous study by further exploring the two best-performing models (NBC Classifier and XGBoost), progressively incorporating a larger number of patients in a prospective way.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Grand Hôpital de CharleroiUpdated: Jul 31, 2025Locations: 1
Eligibility criteria

patients with diffuse large-cell B lymphoma treated in the haematology departmen... [+1]

under 18 years old